BioVentrix develops minimally invasive therapies for treating a dilated left ventricle in patients with ischemic heart failure and reduced ejection fraction. Its lead product, the Revivent TC System, uses myocardial micro-anchor implants to reconstruct the dilated left ventricle and improve chamber efficiency. The company is preparing to submit a pre-market approval (PMA) application to the FDA later this year. Proceeds from the recent financing will support completion of the PMA application, expanded access to allow additional procedures after PMA study enrollment completes, and initial preparations for commercial launch. The company is led by President and CEO Jim Dillon and is based in San Ramon, CA. BioVentrix is a San Ramon, Calif.-based medical device company focused on the Revivent heart failure treatment. Revivent is a transcatheter-based, less invasive ventricular enhancement procedure that reduces the size of the left ventricle without cardiopulmonary bypass or incisions in the heart, according to the company website. The company reported a $12.4 million equity funding round in an equity filing. The round involved 195 unnamed investors and began Jan. 24, closing the same day the filing was reported. BioVentrix will net about $11.4 million after deduction of a sales commission to Taglich Brothers Inc., per the filing. The article did not disclose additional operating metrics or use-of-proceeds details.

Total raised

$61M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2023